Drugmakers criticize new crypto-protection requirements for drug marking in Russia

16 July 2018
moscow-big

Leading Russian and foreign drug manufacturers operating in the local market have warned the national government about the forthcoming rise in prices that will come about as a result of certain innovations introduced by the Russian government in the national pharmaceutical industry.

One of such innovations is the use of crypto-protection during marking of drugs in Russia, reports The Pharma Letter’s local correspondent.

To date, representatives of some leading global drugmakers operating in Russia have appealed to the national government and Parliament with a request to reject the introduction of crypto-protection in the domestic pharmaceutical industry. According to them, this threatens the domestic pharmaceutical industry with isolation, and could also lead to a significant increase in drug prices due to additional costs for producers.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Pharmaceutical